326 related articles for article (PubMed ID: 24467634)
1. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
4. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
5. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
[TBL] [Abstract][Full Text] [Related]
6. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
[TBL] [Abstract][Full Text] [Related]
8. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
9. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Wei X; Zhou P; Lin X; Lin Y; Wu S; Diao P; Xie H; Xie K; Tang P
Tumour Biol; 2014 Oct; 35(10):10213-21. PubMed ID: 25027405
[TBL] [Abstract][Full Text] [Related]
10. ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Qiu L; Liu J; Wang Z; Hu W; Huang Q; Zhou Y
Oncol Rep; 2015 Sep; 34(3):1239-48. PubMed ID: 26165829
[TBL] [Abstract][Full Text] [Related]
11. ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells.
Qiu LN; Zhou YL; Wang ZN; Huang Q; Hu WX
Int J Oncol; 2012 Aug; 41(2):533-40. PubMed ID: 22581170
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
Bellosillo B; Villamor N; López-Guillermo A; Marcé S; Bosch F; Campo E; Montserrat E; Colomer D
Blood; 2002 Sep; 100(5):1810-6. PubMed ID: 12176904
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced apoptosis in chronic lymphocytic leukemia.
Stoetzer OJ; Pogrebniak A; Scholz M; Pelka-Fleischer R; Gullis E; Darsow M; Nüssler V; Wilmanns W
Leukemia; 1999 Nov; 13(11):1873-80. PubMed ID: 10557065
[TBL] [Abstract][Full Text] [Related]
14. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
17. 4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients.
Billard C; Menasria F; Quiney C; Faussat AM; Finet JP; Combes S; Kolb JP
Exp Hematol; 2008 Dec; 36(12):1625-33. PubMed ID: 18922614
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
[TBL] [Abstract][Full Text] [Related]
20. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
